A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton

Bibliography

• KAPLAN FS, GLASER DL, SHORE EM et al.: The phenotype of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):183-188.
   Google Scholar
• SHORE EM, FELDMAN GJ, XU M, KAPLAN FS: The genetics of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):201-204.
   Google Scholar
• GLASER DL, KAPLAN FS: Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):243-250.
   Google Scholar
• LANCHONEY TF, COHEN RB, ROCKE DM, ZASLOFF MA, KAPLAN FS: Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J. Pediatrics (1995) 126:762-764.
   PubMed Web of Science ®Google Scholar
• LUCHETTI W, COHEN RB, HAHN GV et al.: Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (1996) 81:21-25.
   PubMed Web of Science ®Google Scholar
• GLASER DL, ROCKE DM, KAPLAN FS: Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. (1998) 346:110-116.
   PubMedGoogle Scholar
• SCARLETT RF, ROCKE DM, KANTANIE S, PATEL JB, SHORE EM, KAPLAN FS: Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP). Clin. Orthop. (2004) 423:275-279.
   PubMedGoogle Scholar
• KAPLAN FS, TABAS J, GANNON FH, FINKEL G, HAHN GV, ZASLOFF MA: The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J. Bone Joint Surg. Am. (1993) 75-A:220-230.
   Google Scholar
• PIGNOLO RJ, SUDA RK, KAPLAN FS: The fibrodysplasia ossificans progressiva lesion. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):195-200.
   Google Scholar
• GANNON FH, VALENTINE BA, SHORE EM, ZASLOFF MA, KAPLAN FS: Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin. Orthop. (1998) 346:19-25.
   PubMedGoogle Scholar
• GANNON FH, GLASER D, CARON R, THOMPSON LD, SHORE EM, KAPLAN FS: Mast cell involvement in fibrodysplasia ossificans progressiva. Hum. Pathol. (2001) 32:842-848.
   PubMed Web of Science ®Google Scholar
• KAPLAN FS, SHORE EM, GUPTA R et al.: Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):189-193.
   Google Scholar
• COHEN RB, HAHN GV, TABAS J et al.: The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. (1993) 75-A:215-219.
   Google Scholar
• KAPLAN FS, GLASER DL: Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):213-216.
   Google Scholar
• HEBELA N, SHORE EM, KAPLAN FS: Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):205-208.
   Google Scholar
• KAPLAN FS: Fibrodysplasia ossificans progressiva – an historical perspective. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):179-181.
   Google Scholar
• ROSENSTIRN JA: A contribution to the study of myositis ossificans progressiva. Ann. Surg. (1918) 68:468-520, 591-637.
   Google Scholar
• SHORE EM, XU M, FELDMAN GJ et al.: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. (2006) 38:525-527.
   PubMed Web of Science ®Google Scholar
• COUZIN J: Bone disease gene finally found. Science (2006) 312:514-515.
   PubMedGoogle Scholar
• KAPLAN FS, TABAS JA, ZASLOFF MA: Fibrodysplasia ossificans progressiva: a clue from the fly? Calcif. Tissue Int. (1990) 47:117-125.
   PubMed Web of Science ®Google Scholar
• SHAFRITZ AB, SHORE EM, GANNON FH et al.: Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva (FOP). N. Engl. J. Med. (1996) 335:555-561.
   PubMed Web of Science ®Google Scholar
• GANNON FH, KAPLAN FS, OLMSTED E, FINKEL GC, ZASLOFF MA, SHORE E: Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva (FOP). Hum. Pathol. (1997) 28:339-343.
   PubMed Web of Science ®Google Scholar
• AHN J, SERRANO DE LA PENA L, SHORE EM, KAPLAN FS: Paresis of a bone morphogenetic protein antagonist response in a genetic disorder of heterotopic skeletogenesis. J. Bone Joint Surg. Am. (2003) 85-A:667-674.
   PubMedGoogle Scholar
• GLASER DL, ECONOMIDES AN, WANG L et al.: In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J. Bone Joint Surg. Am. (2003) 85-A:2332-2342.
   PubMedGoogle Scholar
• SERRANO DE LA PENA L, BILLINGS PC, FIORI JL, AHN J, KAPLAN FS, SHORE EM: Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J. Bone Miner. Res. (2005) 20:1168-1176.
   PubMed Web of Science ®Google Scholar
• KAPLAN FS, FIORI JL, SERRANO DE LA PENA L, AHN JM, BILLINGS PC, SHORE EM: Dysregulation of BMP4 receptor trafficking and signaling in fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):217-223.
   Google Scholar
• FIORI JL, BILLINGS PC, SERRANO DE LA PENA LS, KAPLAN FS, SHORE EM: Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Res. (2006) 21:902-909.
   PubMed Web of Science ®Google Scholar
• KAPLAN FS, FIORI J, DE LA PENA LS, AHN J, BILLINGS PC, SHORE EM: Dysregulation of the BMP4 signaling pathway in fibrodysplasia ossificans progressiva. Ann. NY Acad. Sci. (2006) 1068:54-65.
   PubMed Web of Science ®Google Scholar
• FISHMAN MC, PORTER JA: A new grammar for drug discovery. Nature (2005) 437:491-493.
   PubMed Web of Science ®Google Scholar
• ZHANG D, SCHWARZ EM, ROSIER RN, ZUSCIK MJ, PUZAS JE, O’KEEFE RJ: ALK2 functions as a type I BMP receptor and induces Indian Hedgehog in chondrocytes during skeletal development. J. Bone Miner. Res. (2003) 18:1593-1604.
   PubMed Web of Science ®Google Scholar
• WANG T, LI B-Y, DANIELSON PD et al.: The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors. Cell (1996) 86:435-444.
   PubMed Web of Science ®Google Scholar
• CHEN YE-GUANG, LIU F, MASSAGUÉ J: Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J. (1997) 16:3866-3876.
   PubMed Web of Science ®Google Scholar
• HUSE M, CHEN Y-G, MASSAGUÉ J. KURIYAN J: Crystal structure of the cytosplasmic domain of the type I TGF-β receptor in complex with FKBP12. Cell (1999) 96:425-436.
   PubMed Web of Science ®Google Scholar
• HUSE M, MUIR TW, XU L, CHEN Y-G, KURIYAN J, MASSAGUÉ J: The TGF-β receptor activation process: an inhibitor-to-substrate binding switch. Mol. Cell (2001) 8:671-682.
   PubMed Web of Science ®Google Scholar
• EBISAWA T, FUKUCHI M, MURAKAMI G et al. Smurf 1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. (2001) 276:12477-12480.
   PubMed Web of Science ®Google Scholar
• TANG L, EBARA S, KAWASAKI S, WAKABAYASHI S, NIKAIDO T, TAKAOKA K: FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol. Int. (2002) 26:75-84.
   PubMed Web of Science ®Google Scholar
• KUGIMIYA F, YANO, OHBA et al.: Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem. Biophys. Res. Commun. (2005) 338:872-879.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, KURISAKI A, YAMAKAWA N, MINAKUCHI K, SUGINO H: FKBP12 functions as an adaptor of the Smad7-Smurf 1 complex on activin type I receptor. J. Mol. Endocrinol. (2006) 36:569-579.
   PubMed Web of Science ®Google Scholar
• KAPLAN, FS, SHORE EM, PIGNOLO RJ, GLASER DL: Animal models of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):229-234.
   Google Scholar
• KAN L, HU M, GOMES WA, KESSLER JA: Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. (2004) 165:1107-1115.
   PubMed Web of Science ®Google Scholar
• YINGLING JM, BLANCHARD KL, SAWYER JS: Development of TGF-β signaling inhibitors for cancer therapy. Nat. Rev. Drug Discov. (2004) 3:1011-1022.
   Google Scholar
• SEBOLT-LEOPOLD JS, ENGLISH JM: Mechanisms of drug inhibition of signaling molecules. Nature (2006) 441:457-462.
   PubMed Web of Science ®Google Scholar
• GRAHAM H, PENG C: Activin receptor-like kinases: structure, function and clinical implications. Endocr. Metab. Immune Disord. Drug Targets (2006) 6:45-58.
   PubMedGoogle Scholar
• KAPLAN FS, GLASER DL, HEBELA N, SHORE EM: Heterotopic ossification. J. Am. Acad. Orthop. Surg. (2004) 12:116-125.
   PubMed Web of Science ®Google Scholar
• PIGNOLO RJ, FOLEY KL: Nonhereditary heterotopic ossification – implications for injury, arthropathy and aging. Clin. Rev. Bone Mineral Metab. (2005) 3(3-4):261-266.
   Google Scholar
• ROUSH W: Protein builds second skeleton. Science (1996) 273:1170.
   PubMed Web of Science ®Google Scholar
• KAPLAN FS: The key to the closet is the key to the kingdom – a common lesson of rare diseases. Orphan Dis. Update (2006) 24:1-8.
   Google Scholar